| Oct 23 |
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
|
| Oct 23 |
Market Chatter: Catalent-Novo Holdings Deal Opposed by Roche CEO
|
| Oct 23 |
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
|
| Oct 23 |
More states considering Medicaid coverage of GLP-1 weight loss drugs
|
| Oct 23 |
Novo Nordisk Lashes Out at Wegovy Copycats. What It Means for Hims & Hers.
|
| Oct 23 |
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
|
| Oct 23 |
Novo tells FDA compounded semaglutide too difficult to make
|
| Oct 23 |
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
| Oct 23 |
Novo Nordisk (NVO): Consistent Growth in Diabetes and Obesity Care
|
| Oct 23 |
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen
|
